Characterization of a New Hsp110 Inhibitor as a Potential Antifungal

Area of Science:

• Mycology
• Biochemistry
• Pharmacology

Background:

• Fungal infections pose a significant global health threat, necessitating the development of novel antifungal agents.
• Heat shock proteins 110 (Hsp110s) are crucial molecular chaperones in eukaryotes and represent a promising target for antifungal drug development.
• Targeting fungal Hsp110s offers a potential strategy to combat drug-resistant fungal pathogens.

Purpose of the Study:

• To evaluate the antifungal potential of a novel compound, 2H, against fungal pathogens.
• To investigate the mechanism of action of 2H, specifically its effect on fungal Hsp110 chaperone activity.
• To assess the pharmacokinetic profile of 2H to determine optimal delivery routes for clinical application.

Main Methods:

• In vitro assessment of 2H's effect on Hsp110 chaperone activity from *Candida auris*.
• Evaluation of 2H's efficacy in inhibiting the growth of *Cryptococcus neoformans*.
• Pharmacokinetic analysis comparing oral and intravenous administration of 2H.

Main Results:

• 2H demonstrated broad-spectrum antifungal activity.
• The compound effectively disrupted the in vitro chaperone activity of *Candida auris* Hsp110.
• 2H inhibited the growth of *Cryptococcus neoformans*.
• Pharmacokinetic studies suggested potentially enhanced efficacy with oral administration compared to intravenous delivery, highlighting the significance of the AUC/MIC ratio.

Conclusions:

• The compound 2H is a promising candidate for targeting fungal Hsp110s to combat fungal infections.
• 2H exhibits significant in vitro antifungal activity against key fungal pathogens.
• Optimizing the pharmacokinetic profile, particularly the AUC/MIC ratio, is crucial for the clinical advancement of 2H as an antifungal therapy.